Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 929 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stereotactic radiotherapy Clear all

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Second Primary Squamous Cell Carcinoma of the Head and Neck
Interventions: Bintrafusp Alfa, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Drug · Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Interventions: Nivolumab, (8gy x 3), Platinum Doublet; Drug · Radiation
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 4
States / cities: St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more

Conditions: Brain Metastases, Non Small Cell Lung Cancer
Interventions: Stereotactic Radiosurgery, Immunotherapy; Radiation · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Spinal Neoplasms
Interventions: Stereotactic Body Radiotherapy; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Cancer
Interventions: Daily Adaptive External Beam Radiation Therapy; Radiation
Lead sponsor: Varian, a Siemens Healthineers Company; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 4
States / cities: Birmingham, Alabama • Duarte, California • St Louis, Missouri + 1 more

Conditions: Invasive Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
Interventions: Dynamic Susceptibility Contrast-MRI (DSC-MRI), Magnetic Resonance Imaging (MRI); Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Lung Cancer
Interventions: Single-fraction stereotactic body radiation therapy (SBRT), Multiple-fraction stereotactic body radiation therapy (SBRT); Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 35
States / cities: Auburn, California • Berkeley, California • Cameron Park, California + 30 more

Conditions: Oligometastasis, Lung Cancer, Colo-rectal Cancer, Prostate Cancer
Interventions: Stereotactic Ablative Radiotherapy, Best Practice; Procedure · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 1 Year and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Durvalumab (MEDI 4736), Radiotherapy; Drug · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 3
States / cities: Los Angeles, California • Denver, Colorado • New York, New York

Conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage IV Non-Small Cell Lung Cancer, Stage IV Skin Melanoma, Melanoma of Unknown Primary
Interventions: Pembrolizumab, Stereotactic Radiosurgery; Biological · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8, Breast Ductal Carcinoma in Situ, Invasive Breast Carcinoma, Triple Negative Breast Carcinoma
Interventions: Best Practice, Stereotactic Body Radiation Therapy, Resection, Sentinel Lymph Node Biopsy, Dietary Intervention, Questionnaire Administration, Quality-of-Life Assessment, Mammography, Biospecimen Collection; Other · Radiation · Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 40 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Breast Cancer, HER2-positive Breast Cancer
Interventions: Lumpectomy or mastectomy, Radiotherapy, Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs; Procedure · Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Lung Cancer
Interventions: Stereotactic Body Radiation Therapy (SBRT); Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions: Nivolumab, Stereotactic Body Radiation Therapy (SBRT); Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more

Conditions: Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: stereotactic radiosurgery; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Dallas, Texas

Conditions: Early Stage Non-Small Cell Lung Cancer
Interventions: Avelumab, SBRT; Drug · Radiation
Lead sponsor: Andrew Sharabi; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: La Jolla, California • Sioux Falls, South Dakota

Conditions: Liver Malignancy
Interventions: Yttrium-90, Selective Internal Radiation Therapy, Stereotactic Body Radiation Therapy; Device · Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Metabolic Diseases
Interventions: human hepatocyte transplantation, Preparative Radiation Therapy; Drug · Radiation
Lead sponsor: Ira Fox; Other
Eligibility: Up to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage I-III Pancreatic Cancer
Interventions: metformin hydrochloride, stereotactic radiosurgery; Drug · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Stage IV Non-Small Cell Lung Cancer
Interventions: Stereotactic Body Radiation Therapy, Maintenance chemotherapy; Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pancreatic Adenocarcinoma
Interventions: Durvalumab, Stereotactic Ablative Body Radiotherapy (SABR); Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Recurrent Pancreatic Adenocarcinoma, Oligometastatic Pancreatic Ductal Adenocarcinoma
Interventions: Chemotherapy, Stereotactic Body Radiation Therapy, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Questionnaire Administration; Drug · Radiation · Procedure + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Metastatic Clear Cell Renal Cell Carcinoma
Interventions: Nivolumab, SAbR; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lung Cancer, Oligometastatic Lung Tumor
Interventions: One fraction stereotactic body radiotherapy, HyperSight, Ethos; Radiation · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer

Evaluation of Single Session Stereotactic Body Radiotherapy

Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach

Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases

Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

A Study of Surgery and Radiotherapy in People With Breast Cancer

SRS Study in Patients With Non-Small Cell Lung Cancer

Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Stereotactic Radiosurgery for Patients With Hepatic Metastases.

SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

Hepatocyte Transplantation for Liver Based Metabolic Disorders

Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer

Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer

Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma

One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors